(MDLZ) Mondelez International - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6092071058

Biscuits, Chocolates, Gums, Candies

Packaged Foods & Meats
Market Cap in USD: 72,383m

IPO / Inception: 2001-06-13
12m vs SPY: -11.7%

EPS (Earnings per Share)

EPS CAGR: -48.68%
EPS Trend: -39.7%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 6.63%
Rev. Trend: 80.8%

Last SUE: 0.23
Qual. Beats: 0

Dividends

Dividend Yield	3.12%
Yield on Cost 5y	3.85%
Yield CAGR 5y	9.90%
Payout Consistency	96.8%
Payout Ratio	68.1%

Risk via 5d forecast
Volatility	23.0%
Value at Risk 5%th	36.5%
Relative Tail Risk	-3.46%

Reward TTM
Sharpe Ratio	0.08
Alpha	-0.11
CAGR/Max DD	-0.03

Character TTM
Hurst Exponent	0.506
Beta	0.070
Beta Downside	-0.038

Drawdowns 3y
Max DD	29.14%
Mean DD	10.45%
Median DD	9.28%

Description: MDLZ Mondelez International December 03, 2025

Mondelez International (NASDAQ: MDLZ) is a global snack-food company that manufactures and markets biscuits, crackers, snack bars, chocolates, gums, candies, and powdered beverages across all major regions, serving a wide array of retail channels from supermarkets to e-commerce platforms.

Key performance indicators from the most recent fiscal year (FY 2023) show net sales of approximately $28.7 billion, a 3.2 % organic growth driven primarily by emerging-market expansion and price-inflation offsets, with an adjusted operating margin of 16.5 %-the highest in the company’s history. The firm’s “Snacking Made Right” strategy targets a 5-6 % CAGR in the high-growth “better-for-you” segment through brands such as CLIF Bar and Tate’s Bake Shop.

Sector-wide drivers that materially affect Mondelez include persistent inflationary pressure on commodity inputs (cocoa, wheat, dairy), shifting consumer preferences toward convenient, protein-rich snacks, and the acceleration of direct-to-consumer and digital sales channels, which now account for roughly 12 % of total revenue and are expected to double by 2026.

For a deeper, data-rich assessment of MDLZ’s valuation dynamics, you might explore the analytical tools available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (3.53b TTM) > 0 and > 6% of Revenue (6% = 2.26b TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -1.92pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -22.22% (prev -21.78%; Δ -0.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 3.58b > Net Income 3.53b (YES >=105%, WARN >=100%)

Net Debt (20.57b) to EBITDA (5.60b) ratio: 3.67 <= 3.0 (WARN <= 3.5)

Current Ratio 0.61 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.30b) change vs 12m ago -3.01% (target <= -2.0% for YES)

Gross Margin 31.05% (prev 38.77%; Δ -7.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 52.45% (prev 50.08%; Δ 2.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 9.76 (EBITDA TTM 5.60b / Interest Expense TTM 437.0m) >= 6 (WARN >= 3)

Altman Z'' 1.87

(A) -0.12 = (Total Current Assets 13.15b - Total Current Liabilities 21.51b) / Total Assets 71.36b

(B) 0.51 = Retained Earnings (Balance) 36.39b / Total Assets 71.36b

(D) 0.55 = Book Value of Equity 24.93b / Total Liabilities 45.13b

Total Rating: 1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.51

1. Piotroski 5.0pt

2. FCF Yield 2.46%

3. FCF Margin 6.08%

4. Debt/Equity 0.84

5. Debt/Ebitda 3.67

6. ROIC - WACC (= 3.05)%

7. RoE 13.44%

8. Rev. Trend 80.76%

9. EPS Trend -39.65%

What is the price of MDLZ shares?

As of January 17, 2026, the stock is trading at USD 57.23 with a total of 12,551,023 shares traded.
Over the past week, the price has changed by +6.13%, over one month by +6.57%, over three months by -6.22% and over the past year by +4.36%.

Is MDLZ a buy, sell or hold?

Mondelez International has received a consensus analysts rating of 4.07. Therefore, it is recommended to buy MDLZ.

Strong Buy: 11
Buy: 8
Hold: 9
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MDLZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	67.5	17.9%
Analysts Target Price	67.5	17.9%
ValueRay Target Price	55.9	-2.3%

MDLZ Fundamental Data Overview January 15, 2026

P/E Trailing = 20.9513
P/E Forward = 17.5131
P/S = 1.9228
P/B = 2.7072
P/EG = 5.0745
Revenue TTM = 37.65b USD
EBIT TTM = 4.26b USD
EBITDA TTM = 5.60b USD
Long Term Debt = 17.13b USD (from longTermDebt, last quarter)
Short Term Debt = 4.19b USD (from shortTermDebt, last quarter)
Debt = 21.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 20.57b USD (from netDebt column, last quarter)
Enterprise Value = 92.95b USD (72.38b + Debt 21.93b - CCE 1.37b)
Interest Coverage Ratio = 9.76 (Ebit TTM 4.26b / Interest Expense TTM 437.0m)
EV/FCF = 40.59x (Enterprise Value 92.95b / FCF TTM 2.29b)
FCF Yield = 2.46% (FCF TTM 2.29b / Enterprise Value 92.95b)
FCF Margin = 6.08% (FCF TTM 2.29b / Revenue TTM 37.65b)
Net Margin = 9.38% (Net Income TTM 3.53b / Revenue TTM 37.65b)
Gross Margin = 31.05% ((Revenue TTM 37.65b - Cost of Revenue TTM 25.95b) / Revenue TTM)
Gross Margin QoQ = 26.81% (prev 32.69%)
Tobins Q-Ratio = 1.30 (Enterprise Value 92.95b / Total Assets 71.36b)
Interest Expense / Debt = 0.10% (Interest Expense 22.0m / Debt 21.93b)
Taxrate = 15.52% (137.0m / 883.0m)
NOPAT = 3.60b (EBIT 4.26b * (1 - 15.52%))
Current Ratio = 0.61 (Total Current Assets 13.15b / Total Current Liabilities 21.51b)
Debt / Equity = 0.84 (Debt 21.93b / totalStockholderEquity, last quarter 26.18b)
Debt / EBITDA = 3.67 (Net Debt 20.57b / EBITDA 5.60b)
Debt / FCF = 8.98 (Net Debt 20.57b / FCF TTM 2.29b)
Total Stockholder Equity = 26.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.92% (Net Income 3.53b / Total Assets 71.36b)
RoE = 13.44% (Net Income TTM 3.53b / Total Stockholder Equity 26.27b)
RoCE = 9.82% (EBIT 4.26b / Capital Employed (Equity 26.27b + L.T.Debt 17.13b))
RoIC = 7.81% (NOPAT 3.60b / Invested Capital 46.15b)
WACC = 4.75% (E(72.38b)/V(94.32b) * Re(6.17%) + D(21.93b)/V(94.32b) * Rd(0.10%) * (1-Tc(0.16)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.24%
[DCF Debug] Terminal Value 86.05% ; FCFF base≈2.85b ; Y1≈2.78b ; Y5≈2.78b
Fair Price DCF = 48.54 (EV 83.20b - Net Debt 20.57b = Equity 62.64b / Shares 1.29b; r=5.90% [WACC]; 5y FCF grow -3.84% → 2.90% )
EPS Correlation: -39.65 | EPS CAGR: -48.68% | SUE: -4.0 | # QB: 0
Revenue Correlation: 80.76 | Revenue CAGR: 6.63% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=-0.001 | Revisions Net=-2 | Analysts=14
EPS next Year (2026-12-31): EPS=3.15 | Chg30d=-0.008 | Revisions Net=-5 | Growth EPS=+8.7% | Growth Revenue=+4.0%

Additional Sources for MDLZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle